<DOC>
	<DOCNO>NCT01898416</DOCNO>
	<brief_summary>The purpose study evaluate efficacy preoperative 5-ALA oral administration subsequently intraoperative tumor bed phototherapy red light laser , adjuvant therapy 3 year rate local tumor recurrence patient desmoid tumor . To evaluate Safety 5-ALA administration . 5 year local recurrence rate .</brief_summary>
	<brief_title>Safety Efficacy Study Using 5-ALA Oral Administration Adjuvant Therapy Rate Local Tumor Recurrence Patients Who Have Desmoids Tumors</brief_title>
	<detailed_description />
	<mesh_term>Fibromatosis , Aggressive</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>1 . Patient resectable histologically confirm desmoid tumor . 2 . Previously treat ( chemotherapy , irradiation surgery ) patient eligible . 3 . Age &gt; 18 year 4 . Signed informed consent prior patient recruitment . 1 . Hepatic enzyme bilirubin &gt; 2X upper limit normal . 2 . Serum creatinine &gt; 2.5 x upper limit normal . 3 . Suspected /documented metastatic disease . 4 . Active uncontrolled infection . 5 . Active second malignant disease ( exclude nonmelanoma skin cancer , situ cervix breast carcinoma ) &lt; 2 year prior study . 6 . Use investigational agent &lt; 30 day prior study . 7 . Patients mentally physically unable comply aspect study . 8 . Any serious medical condition , include presence laboratory abnormality , place subject unacceptable risk participates study confounds experimental ability interpret data study . 9 . Pregnant lactating female . 10 . Known intolerance allergy 5ALA 11 . Suspicious document acute chronic porphyria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>